215 related articles for article (PubMed ID: 27091655)
21. Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders.
Abdel Aziz K; Mohd Ahmed H; Stip E; Aly El-Gabry D
Int Clin Psychopharmacol; 2024 Jul; 39(4):257-266. PubMed ID: 38381917
[TBL] [Abstract][Full Text] [Related]
22. Assessment of inpatient psychiatric readmission risk among patients discharged on an antipsychotic polypharmacy regimen: A retrospective cohort study.
Boskailo E; Malkoc A; McCurry DB; Venter J; Drachman D; Ramos GM
Acta Med Acad; 2017 Nov; 46(2):133-144. PubMed ID: 29338277
[TBL] [Abstract][Full Text] [Related]
23. Antipsychotic polypharmacy and quality of life in patients with schizophrenia treated in primary care in China.
Hou CL; Ma XR; Zang Y; Jia FJ; Lin YQ; Chiu HF; Ungvari GS; Ng CH; Zhong BL; Cao XL; Li Y; Cai MY; Xiang YT
Int J Clin Pharmacol Ther; 2016 Jan; 54(1):36-42. PubMed ID: 26521927
[TBL] [Abstract][Full Text] [Related]
24. Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in China.
Li Q; Xiang YT; Su YA; Shu L; Yu X; Chiu HF; Correll CU; Ungvari GS; Lai KY; Ma C; Wang GH; Bai PS; Li T; Sun LZ; Shi JG; Chen XS; Mei QY; Li KQ; Si TM
Aust N Z J Psychiatry; 2015 Feb; 49(2):129-36. PubMed ID: 24923760
[TBL] [Abstract][Full Text] [Related]
25. The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders.
Hayes RD; Downs J; Chang CK; Jackson RG; Shetty H; Broadbent M; Hotopf M; Stewart R
Schizophr Bull; 2015 May; 41(3):644-55. PubMed ID: 25154620
[TBL] [Abstract][Full Text] [Related]
26. Correlates and predictors of antipsychotic drug polypharmacy in real-life settings: Results from a nationwide cohort study.
Malandain L; Thibaut F; Grimaldi-Bensouda L; Falissard B; Abenhaim L; Nordon C;
Schizophr Res; 2018 Feb; 192():213-218. PubMed ID: 28558905
[TBL] [Abstract][Full Text] [Related]
27. Factors predicting high-dose and combined antipsychotic prescribing in New Zealand: High-dose antipsychotic prescribing.
Burness C; Corbet C; Beyene K; Webby C; Nankivell C; Cabasag P; Hari K; Fraser A; Gray S; Harrison J; Chan AHY
Psychiatry Res; 2021 Aug; 302():113996. PubMed ID: 34126462
[TBL] [Abstract][Full Text] [Related]
28. The hidden magnitude of polypharmacy: using defined daily doses and maximum licensed daily doses to measure antipsychotic load.
Nguyen ML; Sunderland B; Lim S; Hattingh L; Chalmers L
Int J Clin Pharm; 2019 Dec; 41(6):1642-1651. PubMed ID: 31677120
[TBL] [Abstract][Full Text] [Related]
29. Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis.
Matsui K; Tokumasu T; Takekita Y; Inada K; Kanazawa T; Kishimoto T; Takasu S; Tani H; Tarutani S; Hashimoto N; Yamada H; Yamanouchi Y; Takeuchi H
Schizophr Res; 2019 Jul; 209():50-57. PubMed ID: 31182319
[TBL] [Abstract][Full Text] [Related]
30. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study.
Ciapparelli A; Dell'Osso L; Bandettini di Poggio A; Carmassi C; Cecconi D; Fenzi M; Chiavacci MC; Bottai M; Ramacciotti CE; Cassano GB
J Clin Psychiatry; 2003 Apr; 64(4):451-8. PubMed ID: 12716249
[TBL] [Abstract][Full Text] [Related]
31. Mood instability is a common feature of mental health disorders and is associated with poor clinical outcomes.
Patel R; Lloyd T; Jackson R; Ball M; Shetty H; Broadbent M; Geddes JR; Stewart R; McGuire P; Taylor M
BMJ Open; 2015 May; 5(5):e007504. PubMed ID: 25998036
[TBL] [Abstract][Full Text] [Related]
32. Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.
Correll CU; Gallego JA
Psychiatr Clin North Am; 2012 Sep; 35(3):661-81. PubMed ID: 22929872
[TBL] [Abstract][Full Text] [Related]
33. Unraveling ethnic disparities in antipsychotic prescribing among patients with psychosis: A retrospective cohort study based on electronic clinical records.
Wang T; Codling D; Bhugra D; Msosa Y; Broadbent M; Patel R; Roberts A; McGuire P; Stewart R; Dobson R; Harland R
Schizophr Res; 2023 Oct; 260():168-179. PubMed ID: 37669576
[TBL] [Abstract][Full Text] [Related]
34. Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis.
Siskind DJ; Harris M; Phillipou A; Morgan VA; Waterreus A; Galletly C; Carr VJ; Harvey C; Castle D
Epidemiol Psychiatr Sci; 2017 Jun; 26(3):325-337. PubMed ID: 27426892
[TBL] [Abstract][Full Text] [Related]
35. Is the risk of antipsychotic polypharmacy discontinuation dependent on the agents used?
Constantine RJ; Andel R; McPherson M; Tandon R
Psychiatry Res; 2018 May; 263():238-244. PubMed ID: 29195836
[TBL] [Abstract][Full Text] [Related]
36. Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis.
Baandrup L; Sørensen J; Lublin H; Nordentoft M; Glenthoj B
Eur J Health Econ; 2012 Jun; 13(3):355-63. PubMed ID: 21452062
[TBL] [Abstract][Full Text] [Related]
37. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
38. Schizophrenia patients discharged on antipsychotic polypharmacy from a public psychiatric hospital in Taiwan, 2006-2021.
Lin CH; Huang CJ; Lin TC; Chan HY; Chen JJ
Psychiatry Res; 2023 Dec; 330():115575. PubMed ID: 37913621
[TBL] [Abstract][Full Text] [Related]
39. A Non-Interventional Naturalistic Study of the Prescription Patterns of Antipsychotics in Patients with Schizophrenia from the Spanish Province of Tarragona.
Gaviria AM; Franco JG; Aguado V; Rico G; Labad J; de Pablo J; Vilella E
PLoS One; 2015; 10(10):e0139403. PubMed ID: 26427051
[TBL] [Abstract][Full Text] [Related]
40. Factors associated with antipsychotic polypharmacy and high-dose antipsychotics among individuals receiving compulsory treatment in the community.
Gisev N; Bell JS; Chen TF
J Clin Psychopharmacol; 2014 Jun; 34(3):307-12. PubMed ID: 24717256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
